RTX-001 is under clinical development by Resolution Therapeutics and currently in Phase II for Decompensated Cirrhosis. According to GlobalData, Phase II drugs for Decompensated Cirrhosis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the RTX-001 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RTX-001 overview
RTX-001 is under development for the treatment of decompensated cirrhosis of liver and liver fibrosis. It comprises of engineered autologous macrophage cell therapy and is administered through intravenous route. The therapeutic candidate promotes stem cell-mediated liver regeneration.
Resolution Therapeutics overview
Resolution Therapeutics (Resolution TX), a subsidiary of Syncona Portfolio Ltd, is a biotechnology company that provides the development of macrophage cell therapies. The company focuses on treating diseases characterized by life-threatening inflammatory organ damage, particularly chronic liver disease. Resolution TX’s primary product is a macrophage cell therapy designed to treat patients at risk of liver decompensation, aiming to help them avoid the need for a liver transplant. The company’s therapies are based on a proprietary platform of macrophage biology, cell engineering, and manufacturing processes. Its therapies are intended for patients suffering from chronic liver disease. It collaborates with the Scottish National Blood Transfusion Service and Syncona Investment Management Limited for the development and distribution of its therapies. Resolution TX is headquartered in Edinburgh, Scotland, the UK.
For a complete picture of RTX-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
